Drug Profile
Research programme: arrhythmia therapeutics - AstraZeneca
Alternative Names: AZD 3118Latest Information Update: 17 Dec 2007
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Arrhythmias
Most Recent Events
- 17 Dec 2007 Discontinued - Preclinical for Arrhythmias (unspecified route)
- 31 Jul 2007 Preclinical trials in Arrhythmias (unspecified route)